<DOC>
	<DOCNO>NCT00285454</DOCNO>
	<brief_summary>Many people UK ischaemic heart disease . Insufficient blood supply heart muscle mean function inefficiently , lead symptom shortness breath , chest pain excess fluid body . Recently show cell inside bone able produce many different cell type . We investigate new treatment patient 's bone marrow cell take , injected heart attempt produce new blood vessel heart muscle cell . This may lead new treatment ischaemic heart disease .</brief_summary>
	<brief_title>Cell Repair Heart Failure</brief_title>
	<detailed_description>Study Objectives : 1 . Evaluate safety single administration bone marrow mononuclear cell retrograde coronary venous delivery . 2 . Evaluate bioactivity bone marrow mononuclear cell mediate increased perfusion viable underperfused area myocardium . 3 . Evaluate ability bone marrow mononuclear cell improve myocardial function specifically regional wall motion cardiac synchronisation . 4 . Evaluate use potential bioactivity assay clinical outcome assess bone marrow mononuclear cell- induce myocardial change . Study Design : A phase I/II , randomise , double-blind , placebo control , single-centre study bone marrow mononuclear cell percutaneous retrograde coronary venous delivery patient ischaemic heart failure standard revascularisation option . Study Population : Patients symptomatic ischaemic heart failure , amenable conventional revascularisation strategy ( PCI , CABG , LVAD ) transplantation . Independent Eligibility : The result screen procedure compile submit independent interventional cardiologist cardiac surgeon associate study consideration enrolment . It independent reviewer 's responsibility confirm eligibility prior patient participate study . Product : Autologous bone marrow mononuclear , first 6 safety feasibility patient ( open-labelled ) receive sub-population Indium-111 label cell assess feasibility delivery . The remain patient either receive Active : Bone marrow mononuclear cell 5 % HSA Placebo : 5 % HSA Route : Retrograde coronary venous delivery The total dose bone marrow mononuclear cell placebo divide two , administer 10ml bolus selective coronary vein . There significant patient heterogeneity regard size ischaemic viable territory present anatomy venous system . We aim treat two vein , individual SPECT venogram result use direct venous anatomy target . An attempt make cover large area possible patient 's ischaemic viable territory . The total dose cell remain constant patient . Safety : The first 6 patient receive cell adjunct Cardiac resynchronization Therapy ICD . An external Data Safety Monitoring Board also appoint oversee study .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<criteria>1 . Symptomatic ischaemic multivessel coronary artery disease ( CAD ) suitable standard revascularization procedure CABG , PCI , LVAD , heart transplant . 2 . Area reversible inducible ischaemia ( &gt; 10 % LV SPECT ) perform six month prior study treatment . 3 . LVEF &lt; 45 % optimal medical therapy . 4 . NYHA class II IV patient stable optimal medical therapy least 30 day . 5 . Written inform consent agree attend hospital appointment 1 year . 6 . Male female 18 80 year age . 1 . Left ventricular aneurysm thrombus . 2 . Thoracic aortic aneurysm . 3 . Congenital Heart disease 4 . Acute unstable angina , idiopathic cardiomyopathy , lifethreatening ventricular arrhythmia , recent ( less 6 week ) . 5 . Contraindication MRI study procedure . 6 . Presence history cancer ( except low grade fully resolve nonmelanoma skin malignancy ) . 7 . Any comorbidity likely reduce short term survival may interfere functional testing . 8 . Recent myocardial infarction &lt; 6mths . 9 . Cerebral vascular accident &lt; 6mths . 10 . Active hepatitis , receive immunosuppressive therapy , undergoing haemodialysis . 11 . Clinically significant abnormal haematology . 12 . Recent history alcoholism , drug abuse , severe emotional , behavioural , psychiatric problem . 13 . Fertile woman pregnant , nursing , use form contraception . 14 . Receiving experimental medication participate another study within 12 week enrolment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>